These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26164182)

  • 41. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
    Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
    Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.
    Bai B; Huang HQ; Cai QC; Fan W; Wang XX; Zhang X; Lin ZX; Gao Y; Xia YF; Guo Y; Cai QQ; Jiang WQ; Lin TY
    Med Oncol; 2013 Mar; 30(1):339. PubMed ID: 23329306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of baseline, interim and end-of-treatment
    Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
    Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.
    Vaxman I; Bernstine H; Kleinstern G; Hendin N; Shimony S; Domachevsky L; Gurion R; Groshar D; Raanani P; Gafter-Gvili A
    Hematol Oncol; 2019 Apr; 37(2):168-175. PubMed ID: 30734341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic values of baseline, interim and end-of therapy
    Zhou Y; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Cancer Manag Res; 2019; 11():6871-6885. PubMed ID: 31413633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
    Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
    In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interim PET in Diffuse Large B-Cell Lymphoma.
    Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
    J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
    Tychyj-Pinel C; Ricard F; Fulham M; Fournier M; Meignan M; Lamy T; Vera P; Salles G; Trotman J
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):408-15. PubMed ID: 24435770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
    Moon SH; Lee AY; Kim WS; Kim SJ; Cho YS; Choe YS; Kim BT; Lee KH
    Leuk Lymphoma; 2017 Jun; 58(6):1341-1348. PubMed ID: 27718766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
    Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumoral Heterogeneity of Pretreatment 18F-FDG PET Images Predict Disease Progression in Patients With Nasal Type Extranodal Natural Killer/T-cell Lymphoma.
    Ko KY; Liu CJ; Ko CL; Yen RF
    Clin Nucl Med; 2016 Dec; 41(12):922-926. PubMed ID: 27749404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
    Cahu X; Bodet-Milin C; Brissot E; Maisonneuve H; Houot R; Morineau N; Solal-Celigny P; Godmer P; Gastinne T; Moreau P; Moreau A; Lamy T; Kraber-Bodere F; Le Gouill S
    Ann Oncol; 2011 Mar; 22(3):705-711. PubMed ID: 20739714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
    Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
    Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.